Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial
Top Cited Papers
- 7 April 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (7), 1458-1464
- https://doi.org/10.1200/jco.2000.18.7.1458
Abstract
PURPOSE: To investigate whether the addition of cisplatin (CDDP) to hyperfractionation (Hfx) radiation therapy (RT) offers an advantage over the same Hfx RT given alone in locally advanced (stages III and IV) squamous cell carcinoma of the head and neck. PATIENTS AND METHODS: One hundred thirty patients were randomized to receive either Hfx RT alone to a tumor dose of 77 Gy in 70 fractions in 35 treatment days over 7 weeks (group I, n = 65) or the same Hfx RT and concurrent low-dose (6 mg/m2) daily CDDP (group II, n = 65). RESULTS: Hfx RT/chemotherapy offered significantly higher survival rates than Hfx RT alone (68% v 49% at 2 years and 46% v 25% at 5 years; P = .0075). It also offered higher progression-free survival (46% v 25% at 5 years; P = .0068), higher locoregional progression-free survival (LRPFS) (50% v 36% at 5 years; P = .041), and higher distant metastasis-free survival (DMFS) (86% v 57% at 5 years; P = .0013). However, there was no difference between the two treatment groups in the incidence of either acute or late high-grade RT-induced toxicity. Hematologic high-grade toxicity was more frequent in group II patients. CONCLUSION: As compared with Hfx RT alone, Hfx RT and concurrent low-dose daily CDDP offered a survival advantage, as well as improved LRPFS and DMFS.Keywords
This publication has 36 references indexed in Scilit:
- Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck CancerNew England Journal of Medicine, 1998
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology*Biology*Physics, 1995
- Head and Neck CancerNew England Journal of Medicine, 1993
- Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung CancerNew England Journal of Medicine, 1992
- Toxicity and preliminary results from a trial of hyperfractionated radiation with or without simultaneous 5-fluorouracil-cisplatin in advanced head and neck squamous cell carcinomasSeminars in Radiation Oncology, 1992
- Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequenceInternational Journal of Radiation Oncology*Biology*Physics, 1991
- The scope of the problem of primary tumor controlCancer, 1988
- Concurrent daily cisplatin and radiotherapy in locally advanced squamous carcinoma of the head-and-neck and bronchusRadiotherapy and Oncology, 1987
- Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum(II) and irradiationRadiotherapy and Oncology, 1986
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982